What Is The Current and Historic Market Size Analysis Of The Subcutaneous Immunoglobulin (SCIG) Market?
The subcutaneous immunoglobulin (scig) market has seen considerable growth due to a variety of factors.
• The subcutaneous immunoglobulin (SCIG) market has grown rapidly in recent years. It will expand from $12.72 billion in 2024 to $14.52 billion in 2025, with a CAGR of 14.1%.
This growth is driven by the increased prevalence of immunodeficiency disorders, the preference for home-based care, enhanced therapeutic efficacy, better awareness and diagnosis, and more favorable reimbursement policies.
What Is The Forecast For The Subcutaneous Immunoglobulin (SCIG) Market Size?
The subcutaneous immunoglobulin (scig) market is expected to maintain its strong growth trajectory in upcoming years.
• The subcutaneous immunoglobulin (SCIG) market is expected to grow to $24.29 billion by 2029, with a CAGR of 13.7%.
The growth is driven by the rising prevalence of neurological and autoimmune diseases, growing acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, and the growth of healthcare facilities. Key trends include advancements in drug delivery systems, home infusion therapies, antibody therapy developments, and innovations in SCIG formulations.
What Are The Essential Drivers Behind The Growth Of The Subcutaneous Immunoglobulin (SCIG) Market?
The surge in secondary immunodeficiency diseases is anticipated to drive the expansion of the subcutaneous immunoglobulin market. These are conditions characterized by a diminished or compromised immune response due to causes other than the immune system itself. Factors like aging populations, the employment of immunosuppressive therapies, and environmental toxins contribute to the rise of these diseases. Subcutaneous immunoglobulin therapy is an effective method of boosting a weakened immune system, particularly in chronic conditions like HIV or autoimmune diseases, by delivering antibodies that prevent infections and assist with the maintenance of immunological functions during treatment. For instance, statistics from the UK Health Security Agency reported in October 2023 showed a 22% increase from the previous year with 3,805 new HIV diagnoses in England in 2022. Hence, the growth in the occurrence of secondary immunodeficiency diseases is fueling the subcutaneous immunoglobulin market. The subcutaneous immunoglobulin (SCIG) market is also seeing growth due to the rise in neurological disorders. These disorders of the nervous system, which include anatomical, biochemical, or electrical disruptions in the brain, spinal cord, or peripheral nerves, are on the rise due to factors like aging populations, environmental toxins, genetic factors, and lifestyle changes. Subcutaneous immunoglobulin therapy can be especially useful for these disorders as it provides antibodies that regulate the immune response, decrease inflammation, and secure neuromuscular junctions, potentially delaying the progression of the disease and alleviating symptoms. For instance, data from the Alzheimer's Association in March 2022 disclosed that currently 6.5 million Americans over 65 are living with Alzheimer's dementia, and projections suggest this figure could rise to 13.8 million by 2060. Therefore, the growth in neurological disorders is enhancing the expansion of the subcutaneous immunoglobulin market.
How Is The Global Subcutaneous Immunoglobulin (SCIG) Market Divided Into Key Segments?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Pre-Book The Subcutaneous Immunoglobulin (SCIG) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Subcutaneous Immunoglobulin (SCIG) Market?
Leading corporations in the subcutaneous immunoglobulin market are developing a novel formulation called subcutaneous human-klhw, filled with human immune globulins (Ig) to enhance the body's immune response. This formulation is designed for subcutaneous use, specifically to address primary immunodeficiency diseases. For example, the Spain-based pharmaceutical giant, Grifols S.A., rolled out XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022, a product specifically tailored to treat primary immunodeficiency, and as such, responding to a critical healthcare need for individuals with compromised immune systems. XEMBIFY is a pre-packaged solution that simplifies the treatment routine and enhances patient convenience. With a shelf life of 24 months at room temperature, it eliminates the need for cold storage during transport and storage, and this feature makes it extremely versatile across different healthcare environments.
Who Are the Key Players In The Subcutaneous Immunoglobulin (SCIG) Market?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are:
• Pfizer Inc.
• Johnson & Johnson
• Prothena Corporation plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Baxter International Inc.
• CSL Behring
• Lonza Group
• Grifols S.A.
• Octapharma AG
• Dr. Reddy's Laboratories
• Intas pharmaceutical Ltd.
• Emergent BioSolutions Inc.
• Kedrion Biopharma
• LFB group
• Biotest AG
• Argenx SE
• Bio Products Laboratory Ltd.
• ADMA Biologics Inc.
• Sino Biological Inc.
• Bharat Serums and Vaccines Limited (BSV)
• Kamada Pharmaceuticals
• CinnaGen Co.
• Shire plc
What Are The Regional Insights Into The Subcutaneous Immunoglobulin (SCIG) Market?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
